SCHEMBL6866079

SCHEMBL6866079

O=C1CCC(=O)N1CCCCl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 2/20 0.44
FAAH O00519 1/20 0.43
MGLL Q99685 1/20 0.43
CYP1A2 P05177 1/20 0.37
HTR1A P08908 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HTR7 P34969 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM4 P08173 1/20 0.37
CHRM5 P08912 1/20 0.37
CHRM1 P11229 1/20 0.37
DRD2 P14416 1/20 0.37
CHRM3 P20309 1/20 0.37
DRD4 P21917 1/20 0.37
DRD3 P35462 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
HPGD P15428 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6867510 0.93 FAAH (0.46) MEN1KMT2APOLBFAAHMGLL
SCHEMBL6273408 0.91 MEN1 (0.55) MEN1KMT2APOLBFAAHMGLL
SCHEMBL7993059 0.84 POLB (0.38) MEN1KMT2APOLBFAAHMGLL
SCHEMBL14359370 0.84 POLB (0.53) MEN1KMT2APOLBFAAHMGLL
SCHEMBL8829446 0.84 FAAH (0.53) MEN1KMT2APOLBFAAHMGLL
SCHEMBL888672 0.84 MEN1 (0.50) MEN1KMT2APOLBFAAHMGLL
SCHEMBL8829438 0.81 MGLL (0.52) MEN1KMT2APOLBFAAHMGLL
SCHEMBL8862703 0.81 MGLL (0.52) MEN1KMT2APOLBFAAHMGLL
SCHEMBL1982535 0.81 MGLL (0.52) MEN1KMT2APOLBFAAHMGLL
SCHEMBL8626070 0.81 MGLL (0.52) MEN1KMT2APOLBFAAHMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812344-B1 SYTHESIS OF COMPOUNDS FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA RANBAXY LABORATORIES LIMITED (IN) 2004-11-02 US disclosed
US-6420559-B1 THE COMPOUNDS ARE USEFUL FOR TREATMENT OF DISEASE CONDITIONS, SUCH AS PERIPHERAL VASCULAR DISEASE, CONGESTIVE HEART FAILURE, HYPERTENSION AND ESPECIALLY BENIGN PROSTATIC HYPERTROPHY. RANBAXY LABORATORIES LIMITED (IN) 2002-07-16 US disclosed
US-6420366-B1 PERIPHERAL VASCULAR DISEASE, CONGESTIVE HEART FAILURE, HYPERTENSION AND ESPECIALLY BENIGN PROSTATIC HYPERTROPHY. RANBAXY LABORATORIES LIMITED (IN) 2002-07-16 US disclosed
US-6410735-B1 CONGESTIVE HEART FAILURE; HYPOTENSIVE AGENTS; BENGIN PROSTATIC HYPERPLASIA RANBAXY LABORATORIES LIMITED (IN) 2002-06-25 US disclosed
US-6090809-A 1-(4-arylpiperazin-1-yl)-ω-[n-(α..omega.-dicarboximido)]-alkanes useful as uro-selective α1 -adrenoceptor blockers RANBAXY LABORATORIES LIMITED (IN) 2000-07-18 US disclosed
US-6083950-A TREATMENT OF PERIPHERAL VASCULAR DISEASE, CONGESTIVE HEART FAILURE, HYPERTENSION AND ESPECIALLY BENIGN PROSTATIC HYPERTROPHY RANBAXY LABORATORIES LIMITED (IN) 2000-07-04 US disclosed
US-5852018-A Pharmaceutical piperazine compounds XENOVA LIMITED (GB) 1998-12-22 US disclosed